← Leaderboards
Joseph H Antin
Dana-Farber Cancer Institute
$7,618,391
Attributed
$7,618,391
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,142,274 · 8
By mechanism
P01$22,081,245 · 5
U01$2,055,831 · 1
UG1$1,926,323 · 1
U10$1,078,875 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- John G. Gribben$4,031,248
- Stephanie J Lee$27,273,126
- David B. Miklos$5,009,214
- Thomas S. Kupper$36,607,647
- Robert Jon Soiffer$8,435,164
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectImmunologicsRecoveryFutureProphylactic TreatmentPreventAllogenicGraft-Vs-Host DiseaseTransplantationInfectionRegulatory T-LymphocyteFunctional DisorderTrial ComparingCytokineRandomizedRandomized TrialRelapseB-LymphocytesAntibodiesT-LymphocyteChronic Graft Versus Host DiseaseDoseAcute Graft Versus Host DiseaseResponse
Grant awards (47)
BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium$257,014
UG1 · FY2025 · HL · contact PI
BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium$267,000
UG1 · FY2024 · HL · contact PI
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD$203,233
UG1 · FY2023 · HL · contact PI
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD$203,233
UG1 · FY2022 · HL · contact PI
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD$203,233
UG1 · FY2021 · HL · contact PI
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD$203,233
UG1 · FY2020 · HL · contact PI
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD$203,233
UG1 · FY2019 · HL · contact PI
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD$193,072
UG1 · FY2018 · HL · contact PI
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD$193,072
UG1 · FY2017 · HL · contact PI
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT$181,125
U10 · FY2016 · HL · contact PI
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT$181,125
U10 · FY2015 · HL · contact PI
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT$181,125
U10 · FY2014 · HL · contact PI
Mechanisms of GVHD$1,755,269
P01 · FY2013 · CA · contact PI
Novel Approaches to Graft-versus-Host Disease Prevention$263,342
P01 · FY2013 · CA · contact PI
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT$181,125
U10 · FY2013 · HL · contact PI
Administrative Core$159,207
P01 · FY2013 · CA · contact PI
Mechanisms of GVHD$1,867,308
P01 · FY2012 · CA · contact PI
Novel Approaches to Graft-versus-Host Disease Prevention$295,289
P01 · FY2012 · CA · contact PI
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT$181,125
U10 · FY2012 · HL · contact PI
Administrative Core$59,253
P01 · FY2012 · CA · contact PI
Mechanisms of GVHD$1,867,308
P01 · FY2011 · CA · contact PI
Novel Approaches to Graft-versus-Host Disease Prevention$295,858
P01 · FY2011 · CA · contact PI
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT$173,250
U10 · FY2011 · HL · contact PI
Administrative Core$55,103
P01 · FY2011 · CA · contact PI
Mechanisms of GVHD$1,916,255
P01 · FY2010 · CA · contact PI
Novel Approaches to Graft-versus-Host Disease Prevention$303,614
P01 · FY2010 · CA · contact PI
Random Trial of CD8 T-Cell Depletion in PBSC Transplantation$167,937
U01 · FY2010 · HL · contact PI
Administrative Core$56,546
P01 · FY2010 · CA · contact PI
Mechanisms of GVHD$1,953,263
P01 · FY2009 · CA · contact PI
Novel Approaches to Graft-versus-Host Disease Prevention$309,479
P01 · FY2009 · CA · contact PI
Random Trial of CD8 T-Cell Depletion in PBSC Transplantation$163,406
U01 · FY2009 · HL · contact PI
Administrative Core$57,638
P01 · FY2009 · CA · contact PI
Random Trial of CD8 T-Cell Depletion in PBSC Transplantation$159,265
U01 · FY2008 · HL · contact PI
Mechanisms of GVHD$2,025,615
P01 · FY2007 · HL · contact PI
Novel Approaches to GHVD Prevention$482,982
P01 · FY2007 · HL · contact PI
Random Trial of CD8 T-Cell Depletion in PBSC Transplantation$11,163
U01 · FY2007 · HL · contact PI
Mechanisms of GVHD$2,035,506
P01 · FY2006 · HL · contact PI
Novel Approaches to GHVD Prevention$219,051
P01 · FY2006 · HL · contact PI
Random Trial of CD8 T-Cell Depletion in PBSC Transplantation$154,999
U01 · FY2006 · HL · contact PI
Mechanisms of GVHD$2,034,180
P01 · FY2005 · HL
Randomized Trial of CD8 T-Cell Depletion in PBSC Transp*$34,126
U01 · FY2005 · HL
Mechanisms of GVHD$2,056,780
P01 · FY2004 · HL
Randomized Trial of CD8 T-Cell Depletion in PBSC Transp*$405,001
U01 · FY2004 · HL
Mechanisms of GVHD$2,012,399
P01 · FY2003 · HL
Randomized Trial of CD8 T-Cell Depletion in PBSC Transp*$405,000
U01 · FY2003 · HL
Randomized Trial of CD8 T-Cell Depletion in PBSC Transp*$150,000
U01 · FY2002 · HL
Randomized Trial of CD8 T-Cell Depletion in PBSC Transp*$404,934
U01 · FY2001 · HL